State of the art 2025 rare disease country report: Türkiye

This 2025 country report outlines the policy, research, care and support landscape for rare diseases in Türkiye.

This report gives an overview of rare disease activities in Türkiye in 2025, including the national action plan, research and funding, registration and biobanking, organisation of care, newborn screening, diagnostics, patient organisations, information resources, training and orphan medicinal products.

You might also be interested in

November 25 - November 26
Discover practical pathways to repurpose medicines for rare diseases, exchange experiences and best practices between underrepresented and high-performing countries, and build new partnerships at the ERDERA Knowledge Exchange Meeting in Riga on 25-26 November.
This annex explains the specific eligibility, sponsorship, funding and application requirements for Canadian applicants in the ERDERA Clinical Trial Call.
Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.
By connecting national priorities with European initiatives, NMGs support stronger coordination, knowledge exchange and alignment across the rare disease ecosystem.